Cantitate/Preț
Produs

Simulation for Designing Clinical Trials: A Pharmacokinetic-Pharmacodynamic Modeling Perspective

Editat de Hui Kimko, Stephen B. Duffull
en Limba Engleză Hardback – 12 dec 2002
Providing more than just a comprehensive history, critical vocabulary, insightful compilation of motivations, and clear explanation of the state-of-the-art of modern clinical trial simulation, this book supplies a rigorous framework for employing simulation as an experiment, according to a predefined simulation plan, that reflects good simulation practices. The book discusses how to clinical trial designs according to their probability for success, techniques to define distributions of virtual subjects' characteristics, methods to determine the sensitivity of the trial design, and the population relationship between dosing schedules and patient response.
Citește tot Restrânge

Preț: 137540 lei

Preț vechi: 167732 lei
-18%

Puncte Express: 2063

Carte tipărită la comandă

Livrare economică 29 mai-12 iunie


Specificații

ISBN-13: 9780824708627
ISBN-10: 0824708628
Pagini: 424
Ilustrații: illustrations
Dimensiuni: 156 x 234 x 24 mm
Greutate: 0.94 kg
Ediția:New.
Editura: CRC Press
Colecția CRC Press

Public țintă

Academic and Professional Practice & Development

Cuprins

Introduction to Simulation for Design of Clinical Trials. Models for Simulation. Computation in Simulation. Analyses of the Simulations. Perspectives on Clinical Trial Simulation. Applications. Index.

Descriere

Providing more than just a comprehensive history, critical vocabulary, insightful compilation of motivations, and clear explanation of the state-of-the-art of modern clinical trial simulation, this book supplies a rigorous framework for employing simulation as an experiment, according to a predefined simulation plan, that reflects good simulation practices. The book discusses how to design clinical trials according to their probability for success, techniques to define distributions of virtual subjects' characteristics, methods to determine the sensitivity of the trial design, and the population relationship between dosing schedules and patient response.